Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.3, 2007-01, pp. : 253-266

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Insulin glargine improves glycaemic control in type 1 and 2 diabetes

Inpharma, Vol. 1, Iss. 1458, 2004-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus

By Chatterjee Sudesna Tringham Jennifer R Davies Melanie J

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1357-1371

Informa Healthcare

Access to resources Recommend Favorite

A combination of insulin glargine and rapid-acting insulin analogue (RAIA) is effective for the treatment of children with type 1 diabetes.

Inpharma, Vol. 1, Iss. 1636, 2008-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes

By Palmer Andrew J.

PharmacoEconomics, Vol. 24, Iss. 9, 2006-01 ,pp. : 927-929

Adis International

Access to resources Recommend Favorite

Insulin detemir weighs in against insulin glargine in type 2 diabetes

Inpharma, Vol. 1, Iss. 1545, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite